<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00681421</url>
  </required_header>
  <id_info>
    <org_study_id>IMS-OKA0201</org_study_id>
    <nct_id>NCT00681421</nct_id>
  </id_info>
  <brief_title>Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Esophageal Cancer</brief_title>
  <official_title>Phase I/II Study of Multiple-Vaccine Therapy Using Epitope Peptide Restricted to HLA-A*0201 in Treating Patients With Refractory Esophageal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tokyo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Human Genome Center, Institute of Medical Science, University of Tokyo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tokyo University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and time to progression of HLA-A*0201
      restricted epitope peptides URLC10, VEGFR1 and VEGFR2 emulsified with Montanide ISA 51.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      URLC10 has been identified as cancer specific molecules especially in non small cell lung
      cancer using genome-wide expression profile analysis by cDNA microarray technique. In a prior
      study, it has been shown that URLC10 is upregulated in human esophageal tumors. VEGF receptor
      1 and 2 are essential targets to tumor angiogenesis, and we identified that peptides derived
      from these receptors significantly induce the effective tumor specific CTL response in vitro
      and vivo. According to these findings, in this trial, we evaluate the safety, immunological
      and clinical response of those peptides. Patients will be vaccinated twice a week for 8
      weeks. On each vaccination day, the URLC10-117 peptide(1mg), VEGFR1 peptide(1mg) and VEGFR2
      peptide(1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
      Repeated cycles of vaccine will be administered until patients develop progressive disease or
      unacceptable toxicity, whichever occurs first. In the phase I study, we evaluate the safety
      and tolerability of these peptide vaccines. In the following phase II study, we evaluate the
      immunological and clinical response of this vaccine therapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety(Phase I:toxicities as assessed by NCI CTCAE version3) and efficacy(Phase II:Feasibility as evaluated by RECIST)</measure>
    <time_frame>two months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate immunological responses</measure>
    <time_frame>two months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">14</enrollment>
  <condition>Esophageal Cancer</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>URLC10, VEGFR1 and VEGFR2</intervention_name>
    <description>Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, the URLC10 peptide (1mg), VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Advanced or recurrent esophageal cancer

          -  Resistant against conventional chemotherapy or difficult to continue the chemotherapy
             due to intolerable side effect(s)

          -  ECOG performance status 0-2

          -  Life expectancy &gt; 3 months

          -  HLA-A*0201

          -  Laboratory values as follows 2000/mm3&lt;WBC&lt;15000/mm3 Platelet count&gt;100000/mm3
             Bilirubin &lt; 3.0mg/dl Asparate transaminase &lt; 150IU/L Alanine transaminase &lt; 150IU/L
             Creatinine &lt; 3.0mg/dl

          -  Able and willing to give valid written informed consent

        Exclusion Criteria:

          -  Pregnancy (woman of childbearing potential:Refusal or inability to use effective means
             of contraception)

          -  Breastfeeding

          -  Active or uncontrolled infection

          -  Unhealed external wound

          -  Concurrent treatment with steroids or immunosuppressing agent

          -  Prior chemotherapy, radiation therapy, and/or immunotherapy within 4 weeks

          -  Uncontrolled brain and/or intraspinal metastasis

          -  Decision of unsuitableness by principal investigator or physician-in-charge
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Naohide Yamashita, MD/PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Tokyo University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Institutute of Medical Science, University of Tokyo</name>
      <address>
        <city>4-6-1, Shirokanedai, Minato-ku</city>
        <state>Tokyo</state>
        <zip>108-8639</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <reference>
    <citation>Okabe H, Satoh S, Kato T, Kitahara O, Yanagawa R, Yamaoka Y, Tsunoda T, Furukawa Y, Nakamura Y. Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression. Cancer Res. 2001 Mar 1;61(5):2129-37.</citation>
    <PMID>11280777</PMID>
  </reference>
  <reference>
    <citation>Hasegawa S, Furukawa Y, Li M, Satoh S, Kato T, Watanabe T, Katagiri T, Tsunoda T, Yamaoka Y, Nakamura Y. Genome-wide analysis of gene expression in intestinal-type gastric cancers using a complementary DNA microarray representing 23,040 genes. Cancer Res. 2002 Dec 1;62(23):7012-7.</citation>
    <PMID>12460921</PMID>
  </reference>
  <reference>
    <citation>Takahashi M, Tsunoda T, Seiki M, Nakamura Y, Furukawa Y. Identification of membrane-type matrix metalloproteinase-1 as a target of the beta-catenin/Tcf4 complex in human colorectal cancers. Oncogene. 2002 Aug 29;21(38):5861-7.</citation>
    <PMID>12185585</PMID>
  </reference>
  <reference>
    <citation>Ishizaki H, Tsunoda T, Wada S, Yamauchi M, Shibuya M, Tahara H. Inhibition of tumor growth with antiangiogenic cancer vaccine using epitope peptides derived from human vascular endothelial growth factor receptor 1. Clin Cancer Res. 2006 Oct 1;12(19):5841-9.</citation>
    <PMID>17020992</PMID>
  </reference>
  <reference>
    <citation>Wada S, Tsunoda T, Baba T, Primus FJ, Kuwano H, Shibuya M, Tahara H. Rationale for antiangiogenic cancer therapy with vaccination using epitope peptides derived from human vascular endothelial growth factor receptor 2. Cancer Res. 2005 Jun 1;65(11):4939-46.</citation>
    <PMID>15930316</PMID>
  </reference>
  <verification_date>November 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2008</study_first_submitted>
  <study_first_submitted_qc>May 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2008</study_first_posted>
  <last_update_submitted>November 18, 2009</last_update_submitted>
  <last_update_submitted_qc>November 18, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2009</last_update_posted>
  <responsible_party>
    <name_title>Naohida Yamashita, MD/PhD</name_title>
    <organization>The Institute of Medical Science, The University of Tokyo</organization>
  </responsible_party>
  <keyword>Peptide Vaccine</keyword>
  <keyword>URLC10</keyword>
  <keyword>VEGFR1</keyword>
  <keyword>VEGFR2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

